Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Clin Cancer Res. 2014 Mar 31;20(11):2922–2932. doi: 10.1158/1078-0432.CCR-13-1246

Figure 4. Zoledronic acid inhibits bone resorption and reduces tumour take in ovariectomised mice.

Figure 4

(a) Experimental outline. (b) Histogram showing mean ± SEM % of mice with detectable bone tumours in control and zoledronic acid treated ovariectomised and sham operated mice 35 days following tumour cell inoculation. (c) Bone volume compared with trabecular volume 28 days following ovariectomy and 31 days following zoledronic acid treatment in mice pre-injected with MDA-MB-231 cells (mean ± SEM). (d) μCT images representing bone architecture at the end of the experimental protocol. * represents a p value of < 0.05 compared with sham control and ** a p value of < 0.05 compared with sham control and OVX control.